European Commission Approves Pfizer's ELREXFIO® for Rel

Conditional marketing authorization is based on clinically meaningful response rates, duration of response, and safety from the Phase 2 MagnetisMM-3 trial



ELREXFIO is an off-the-shelf ,...

Related Keywords

Australia , Singapore , Liechtenstein , Iceland , Brazil , United Kingdom , Norway , Canada , Switzerland , Al Hamed , Chris Boshoff , Myeloma Research Foundation , Pfizer Inc , Exchange Commission , Youtube , Healthcare Products Regulatory Agency , End Results Program , Linkedin , Drug Administration , Approval Program , Committee For Medicinal Products Human Use , National Cancer Institute , European Medicines Agency , European Commission , Oncology Research , World Health Organization , Pfizer , Chief Oncology Research , Development Officer , Executive Vice President , Medicinal Products , Human Use , Accelerated Approval Program , Project Orbis , United Kingdom Medicines , Medicine Designation , Innovation Passport , Mitigation Strategy , Wallet Card , Prescribing Information , Pfizer Oncology , Breakthroughs That Change Patient , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future Results , Accessed August , Patients Europe , Patients Guide , Updated May , Health Organization , Multiple Myeloma , End Results , Cancer Stat Facts , Lymphoma Myeloma , Markets ,